» Articles » PMID: 9409568

Influence of Preoperative Transarterial Lipiodol Chemoembolization on Resection and Transplantation for Hepatocellular Carcinoma in Patients with Cirrhosis

Overview
Journal Ann Surg
Specialty General Surgery
Date 1997 Dec 31
PMID 9409568
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the impact of preoperative transarterial lipiodol chemoembolization (TACE) in the management of patients undergoing liver resection or liver transplantation for hepatocellular carcinoma.

Patients And Methods: TACE was performed before surgery in 49 of 76 patients undergoing resection and in 54 of 111 patients undergoing liver transplantation. Results were retrospectively analyzed with regard to the response to treatment, the type of procedure performed, the incidence of complications, the incidence and pattern of recurrence, and survival.

Results: In liver resection, downstaging of the tumor by TACE (21 of 49 patients [42%]) and total necrosis (24 of 49 patients [50%]) were associated with a better disease-free survival than either no response to TACE or no TACE (downstaging, 29% vs. 10% and 11 % at 5 years, p = 0.08 and 0.10; necrosis, 22% vs. 13% and 11% at 5 years, p = 0.1 and 0.3). Five patients (10%) with previously unresectable tumors could be resected after downstaging. In liver transplantation, downstaging of tumors >3 cm (19 of 35 patients [54%]) and total necrosis (15 of 54 patients [28%]) were associated with better disease-free survival than either incomplete response to TACE or no TACE (downstaging, 71 % vs. 29% and 49% at 5 years, p = 0.01 and 0.09; necrosis, 87% vs. 47% and 60% at 5 years, p = 0.03 and 0.14). Multivariate analysis of the factors associated with response to TACE showed that downstaging occurred more frequently for tumors >5 cm.

Conclusions: Downstaging or total necrosis of the tumor induced by TACE occurred in 62% of the cases and was associated with improved disease-free survival both after liver resection and transplantation. In liver resection, TACE was also useful to improve the resectability of primarily unresectable tumors. In liver transplantation, downstaging in patients with tumors >3 cm was associated with survival similar to that in patients with less extensive disease.

Citing Articles

Investigating the Influence of Preoperative Trans Arterial Embolization (TAE) and Predictive Potential of Circulating Tumor Cells (CTCs) in Prognosis of Hepatocellular Carcinoma.

Patkar S, Shetty O, Vyas K, Vengurlekar V, Kamble V, Shetty N J Clin Exp Hepatol. 2024; 14(6):101445.

PMID: 38975607 PMC: 11222936. DOI: 10.1016/j.jceh.2024.101445.


British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.

Suddle A, Reeves H, Hubner R, Marshall A, Rowe I, Tiniakos D Gut. 2024; 73(8):1235-1268.

PMID: 38627031 PMC: 11287576. DOI: 10.1136/gutjnl-2023-331695.


Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma.

Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L J Hepatocell Carcinoma. 2023; 10:1709-1721.

PMID: 37817914 PMC: 10560606. DOI: 10.2147/JHC.S432062.


European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.

Claasen M, Sneiders D, Rakke Y, Adam R, Bhoori S, Cillo U Transpl Int. 2023; 36:11648.

PMID: 37779513 PMC: 10533675. DOI: 10.3389/ti.2023.11648.


Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study.

Mo A, Zhang Q, Xia F, Huang Z, Peng S, Cao W Cancer Med. 2022; 12(7):7734-7747.

PMID: 36540041 PMC: 10134378. DOI: 10.1002/cam4.5529.


References
1.
Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

2.
Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M . Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology. 1996; 23(5):1112-8. DOI: 10.1002/hep.510230527. View

3.
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S . Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983; 148(2):397-401. DOI: 10.1148/radiology.148.2.6306721. View

4.
Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H . Hepatocellular carcinoma detected by iodized oil. Radiology. 1985; 154(1):19-24. DOI: 10.1148/radiology.154.1.2981112. View

5.
Sheu J, SUNG J, Chen D, Yang P, Lai M, Lee C . Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985; 89(2):259-66. DOI: 10.1016/0016-5085(85)90324-5. View